t(11;14)

MCL Literature Feed

888 papers on mantle cell lymphoma from PubMed. Updated daily.

ADCBCL2iBTKiCAR-TCDK4/6iCNSMRDPI3KiTP53-mutatedbiomarkersbispecificblastoidcase reportchemotherapyconsolidationelderlyepidemiologyfrontlinegenomicsguidelines
Modern Management of Mantle Cell Lymphoma.
Tobias Tix, Anita Kumar, Toby A Eyre et al.·American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting·Jun 1, 2026
IL-16 production is a mechanism of resistance to BTK inhibitors and R-CHOP in lymphomas.
Alberto J Arribas, Eleonora Cannas, Giulio Sartori et al.·Blood·May 29, 2026
Treatment evolution and survival impact of consolidation therapies in mantle cell lymphoma: insights from an Asia-Pacific real-world registry.
Hyungwoo Cho, Koji Kato, Jason Yongsheng Chan et al.·Blood cancer journal·May 29, 2026
A Phase Ib Trial of Copanlisib in Combination with Venetoclax in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma-SAKK 66/18 Trial.
Maria Cristina Pirosa, Dagmar Hess, Fatime Krasniqi et al.·Cancers·May 28, 2026
Significant variations in first-line mantle cell lymphoma care-an Australasian Lymphoma and Related Diseases Registry study.
Zoe Loh, Eliza Chung, Cameron Wellard et al.·Leukemia & lymphoma·May 26, 2026
Get the weekly MCL digest

The 5 most important MCL papers of the week, summarized. Free, no spam, unsubscribe anytime.

Towards the Definition of a Prognostic Model for Mantle Cell Lymphoma.
Simone Ferrero, Riccardo Francia, Marco Ladetto et al.·Studies in health technology and informatics·May 21, 2026
First BCL-2 Inhibitor Approved for Mantle Cell Lymphoma.
·Cancer discovery·May 21, 2026
"Immunologic Dream Team": BiTEs peri-allotransplant to redirect donor lymphocytes towards GVL.
Lorenzo Iovino, Mazyar Shadman, Filippo Milano et al.·Blood advances·May 20, 2026
End of transplantation's reign in mantle cell lymphoma.
Judith Trotman, Janlyn Falconer·Lancet (London, England)·May 16, 2026
Addition of autologous stem-cell transplantation to an ibrutinib-containing first-line treatment in patients aged 18-65 years with mantle cell lymphoma (TRIANGLE): 4·5-year follow-up of a three-arm, randomised, open-label, phase 3 superiority trial of the European MCL Network.
Martin Dreyling, Jeanette Doorduijn, Eva Giné et al.·Lancet (London, England)·May 16, 2026
Get the weekly MCL digest

The 5 most important MCL papers of the week, summarized. Free, no spam, unsubscribe anytime.

Design, synthesis, and biological evaluation of 2-morpholino-4H-chromen-4-one derivatives as a potent dual PI3K/BRD4 inhibitors.
Krishnaiah Maddeboina, Bharath Yada, Cody C McHale et al.·European journal of medicinal chemistry·May 15, 2026
Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis Following CAR T-Cell Therapy: Results of a Real-World Study.
Inna Shaforostova, Marie-Noelle Kronig, Katja Seipel et al.·Cancers·May 14, 2026
Development and validation of a novel prognostic index for mantle cell lymphoma integrating TP53 mutations (MIPI53).
Miguel Bastos-Boente, Alejandro Medina-Herrera, Almudena Navarro-Bailón et al.·British journal of haematology·May 14, 2026
Leukemic Non-Nodal Mantle Cell Lymphoma Presenting with Traumatic Splenic Rupture.
Moinul Haque, Razie Amraei, Krasimira A Rozenova·Hematology reports·May 13, 2026
Population-based survival after mantle cell lymphoma in Norway and Denmark: Limited impact of earlier BTKi access.
Mikkel Runason Simonsen, Marianne B Jerm, Tom B Johannesen et al.·British journal of haematology·May 12, 2026
Get the weekly MCL digest

The 5 most important MCL papers of the week, summarized. Free, no spam, unsubscribe anytime.

Proteasome inhibition enhances lysosome-mediated targeted protein degradation.
Ahmed M Elshazly, Nayyerehalsadat Hosseini, Janakiram Vangala et al.·Cell death & disease·May 11, 2026
Cutaneous Involvement by Blastoid Mantle Cell Lymphoma Presenting as Cervical Abscess: A Rare Extranodal Diagnostic Challenge.
Shreya Sharma, Ankita Soni, Manjit Kaur Rana et al.·Journal of cutaneous pathology·May 10, 2026
More than an attachment module: covalent inhibitor warheads influence BTK dynamics and function.
Raji E Joseph, Robert G Britton, David Yin-Wei Lin et al.·bioRxiv : the preprint server for biology·May 8, 2026
Cyclin-Dependent Kinase 5 Contributes to Bruton's Tyrosine Kinase Inhibitor Resistance via the IRE1α/XBP1 Axis in Mantle Cell Lymphoma.
Alexey Danilov, Sonia Rodriguez-Rodriguez, Dan Vuong et al.·Research square·May 8, 2026
Classic Hodgkin lymphoma with IGH::CCND1 rearrangement: evidence of clonal relation to preceding mantle cell lymphoma.
Ahmed A Ahmed, Saber Tadros·Blood·May 7, 2026
Get the weekly MCL digest

The 5 most important MCL papers of the week, summarized. Free, no spam, unsubscribe anytime.

Association Between Progression-Free Survival and Overall Survival in Mantle Cell Lymphoma: A Trial-level Surrogate Endpoint Analysis.
Alexander M Gorzewski, Christina Raker, Victoria A Gill et al.·Clinical lymphoma, myeloma & leukemia·May 5, 2026
Accessing BTK Inhibitors and Other Novel Therapies for Mantle Cell Lymphoma: Are We All Invited to the Party?
Andre Costa Meireles, Paloma Martinho Resende, Laura Korin et al.·Clinical lymphoma, myeloma & leukemia·May 4, 2026
An Evaluation of Ibrutinib and Ixazomib in Patients With Relapsed/Refractory Mantle Cell Lymphoma: PrE0404.
Jonathon B Cohen, Craig A Portell, Mehdi Hamadani et al.·Clinical lymphoma, myeloma & leukemia·May 4, 2026
Post CAR-T Measurable Residual Disease Monitoring in Mantle Cell Lymphoma Enables Early Detection of Disease Relapse.
Snegha Ananth, Neha Agarwal, Bita Sahaf et al.·American journal of hematology·May 4, 2026
Comparative Risk of Adverse Cardiovascular Outcomes with Zanubrutinib vs Ibrutinib in B-Cell Malignancies: A Large Real-World Propensity-Matched Analysis.
Usama Qamar, Zeeshan Imtiaz, Muhammad Hassan Jan et al.·The American journal of cardiology·May 3, 2026
Get the weekly MCL digest

The 5 most important MCL papers of the week, summarized. Free, no spam, unsubscribe anytime.

Varnimcabtagene autoleucel (ARI-0001) in relapsed or refractory mantle cell lymphoma.
Nil Albiol, Nuria Martínez-Cibrián, Amanda Isabel Pérez et al.·HemaSphere·May 1, 2026
Real-World Treatment Patterns and Healthcare Resource Utilization of Bruton Tyrosine Kinase Inhibitors for the Treatment of Mantle Cell Lymphoma in the United States.
Bijal Shah, Mei Xue, Wesley Furnback et al.·Hematological oncology·May 1, 2026
Correction to 'Mucin 20 Modulates Proteasome Capacity Through c-Met Signalling to Increase Carfilzomib Sensitivity in Mantle Cell Lymphoma'.
·Journal of cellular and molecular medicine·May 1, 2026
Dissecting minimal residual disease dynamics to improve outcome prediction in mantle cell lymphoma: Data from the Fondazione Italiana Linfomi (FIL)-MCL0208 clinical trial.
Francesca Cordero, Simone Ferrero, Simone Pernice et al.·HemaSphere·May 1, 2026
Eprenetapopt in combination with Palbociclib exerts synthetic lethality in mantle cell lymphoma.
Ling Dong, Yue Zhang, Fei Chen et al.·Translational oncology·May 1, 2026
← PreviousPage 4 of 30Next →